US DOJ, SEC receive corruption complaints against Western pharma in Russia

US DOJ and SEC have received complaints alleging corruption and collusion in Russian state drug procurement involving Novartis, MSD, AstraZeneca, Eli Lilly, and others, including bonus payments to local partners. The claims are unverified and may reflect ongoing scrutiny of pharma practices in Russia. This could signal expanded US enforcement against Western firms operating in Russia, with reputational and legal risks for the companies involved.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works